EUVIMEDEUVIMED entdecken
Open Access

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine

Behnaz Eshaghi iD, Erika Yan Wang, Sevinj Mursalova, Timothy A Forster, Ninaad Lasrado iD, Jinbi Tian, Dorin Artzi iD, Stacey Qiaohui Lin iD, Zongting Wu iD, Xin Yang, Wontaek Chung iD, Ilin Sadeghi iD und 13 weitere

Science Advances · 05.06.2026 · 12 (23)

DOI: 10.1126/sciadv.aea5433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 05.06.2026. Verfasst von Behnaz Eshaghi und 24 weiteren Autor:innen. Beteiligte Einrichtung: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, Immunity, Mucosal, Intestinal Mucosa, Nanovaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enteric pathogens are a major contributor to the global disease burden, necessitating vaccines capable of inducing robust gastrointestinal mucosal immunity. Achieving this response is especially challenging with inactivated or subunit vaccines, which lack the ability of live-attenuated formulations to mimic the natural infection process needed to induce strong intestinal mucosal immunity. Specifically, the inactivated polio vaccine (IPV), administered parenterally, elicits strong systemic immunity but fails to induce the mucosal IgA responses required to fully block poliovirus transmission, a critical step toward complete eradication. To address this limitation, we developed a clinically translatable and scalable nanoparticle-based intestinal mucosal adjuvant by encapsulating Am80, a small hydrophobic molecule known to promote intestinal mucosal immunity, within nanoparticles (NPs) designed for lymph node delivery, without requiring antigen modification, encapsulation, or adsorption. Encapsulation in NPs eliminated the need for the use of organic solvents, reduced toxicity, and prevented degradation, while lipid nanoparticles (Am80-LNPs) were engineered for sustained release over 3 to 5 days with high encapsulation efficiency (78 ± 9%). Cy5-labeled Am80-LNPs localized to draining lymph nodes within 6 hours and were retained for up to 72 hours. Coadministration of Am80-LNPs with the licensed IPV-2 in a Wistar rat model significantly boosted IPV-2–specific fecal IgA by 20-fold compared to IPV-2 alone and threefold over free Am80. These findings demonstrate that Am80-LNPs significantly enhance IPV-2–specific mucosal immunity in vivo and suggest their potential as a potent mucosal adjuvant against other enteric pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicImmunity, MucosalIntestinal MucosaNanovaccinesPoliomyelitisPoliovirus Vaccine, InactivatedAnimalsFemaleRatsImmunizationImmunoglobulin ALipidsLymph NodesNanoparticlesLiposomesHumans

Substanzen

Adjuvants, ImmunologicImmunoglobulin ALipid NanoparticlesLipidsNanovaccinesPoliovirus Vaccine, InactivatedLiposomes

Autor:innen und Institutionen

  • David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Department of Electrical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • The Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.
  • The Ragon Institute of MGH, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.

ORCID-Profile: Behnaz Eshaghi, Ninaad Lasrado, Dorin Artzi, Stacey Qiaohui Lin, Zongting Wu, Wontaek Chung, Ilin Sadeghi, Alicia Lau, Aki Gurram, Bernardo A Mainou, Yi Liu, Dan H Barouch, Ulrich von Andrian, Robert Langer, Ana Jaklenec

Förderung

  • Bill and Melinda Gates Foundation

Zitieren

APA

Eshaghi, B., Wang, E. Y., Mursalova, S., Forster, T. A., Lasrado, N., Tian, J., Artzi, D., Lin, S. Q., Wu, Z., Yang, X., Chung, W., Sadeghi, I., Garcia, J., Chen, Z., Sheridan, O., Das, R., Lau, A., Gurram, A., Mainou, B. A., …, & Jaklenec, A. (2026). Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine. Science Advances, 12(23). https://doi.org/10.1126/sciadv.aea5433

Vancouver

Eshaghi B, Wang EY, Mursalova S, Forster TA, Lasrado N, Tian J, et al. Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine. Science Advances. 2026;12(23). doi:10.1126/sciadv.aea5433

BibTeX
@article{Eshaghi2026,
  author = {Eshaghi, Behnaz and Wang, Erika Yan and Mursalova, Sevinj and Forster, Timothy A and Lasrado, Ninaad and Tian, Jinbi and Artzi, Dorin and Lin, Stacey Qiaohui and Wu, Zongting and Yang, Xin and Chung, Wontaek and Sadeghi, Ilin and Garcia, Johnny and Chen, Ziqi and Sheridan, Olivia and Das, Rishi and Lau, Alicia and Gurram, Aki and Mainou, Bernardo A and Jones, Kathryn A V and Liu, Yi and Barouch, Dan H and von Andrian, Ulrich and Langer, Robert and Jaklenec, Ana},
  title = {Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {23},
  doi = {10.1126/sciadv.aea5433}
}
Kostenlos starten →